drugset / Trial / NCT03804645

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

NCT03804645

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone. This study will assess the pharmacokinetics (PK) of four different Formulations of AZD9977 (Part A) and influence of food and lower dose of a selected formulation (Part B) in healthy male subjects.

Timeline

Start
2019-02-05
Primary completion
2019-04-16
Completion
2019-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject balcinrenone Small molecule 50 mg Oral
Subject balcinrenone Small molecule 300 mg Oral

Indications